Abstract #4406

The Addition of Rituximab to First-Line Chemotherapy for Newly-Diagnosed Diffuse Large B-Cell Lymphoma Does Not Modify the Prediction of Therapy Outcome by Phosphorus MR Spectroscopy

Fernando Arias-Mendoza¹, Kristen Zakian², Geoffrey S. Payne³, Marion Stubbs⁴, Hamed Mojahed¹, Amita Shukla-Dave², Franklyn Howe⁵, Harish Poptani⁶, Mitchell R. Smith<su

¹Columbia University Medical Center, New York, NY, United States; ²Memorial Sloan-Kettering Cancer Center, New York, NY, United States; ³Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; ⁴Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom; ⁵St. George's Hospital, London, United Kingdom; ⁶University of Pennsylvania Medical Center, Philadelphia, PA, United States; ⁷Fox Chase Cancer Center, Philadelphia, PA, United States; ⁸New York University Medical Center, New York, NY, United States; ⁹Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; ¹⁰Medical University of South Carolina, Charleston, SC, United States

We have used in vivo phosphorus MR spectroscopy to measure phosphoethanolamine and phosphocholine in tumors of newly diagnosed diffuse large B-cell lymphoma patients prior to the start of first-line chemotherapy and normalized to nucleoside triphosphates (PME/NTP) with the aim to assess whether the correlation of the pretreatment tumor PME/NTP value with treatment outcome differs between those patients treated with first-line chemotherapy alone and those treated with added rituximab.